

藥物毒物一把抓（二）： Lexi-Comp藥學資料庫

台灣獨家代理 - 飛資得醫學資訊

業務專員 陳永祥

tesochen@flysheet.com.tw

資料庫為**輔助**醫療人員決策之用
，應用時應**綜合**各文獻內容(包含
仿單.Lexicomp, Micromedex等)
及臨床判斷，以求周全。


Outline

- 什麼是 Lexicomp®
- 在 Lexicomp® Online™ 瀏覽與檢索
- 範例與討論

什麼是 Lexicomp®

Wolters Kluwer Health


- 屬於成立於 1836 年的荷蘭 Wolters Kluwer 集團
- 旗下品牌包含



Lexicomp®



Lexicomp® 的應用範圍



Lexicomp® 的源起


- 成立已逾 30 年的藥品與臨床醫學資訊出版公司
- 出版超過 30 本的專業藥學參考書
- 全球多達兩百人的團隊* (醫、藥、護及資訊人員)
- 24/7 維護資料內容



* Clinical Team of Wolters Kluwer Health. From <http://www.lexi.com/home/wk-health-clinical-solutions/clinical-team/>

Lexicomp® 資料庫的優勢

- 提供多個資料來源
 - Lexicomp®
 - Facts & Comparisons®
 - AHFS®
- 基本版即包含所有模組
- 全球專業團隊每日更新
- 精簡、關鍵、快速、能解決臨床問題的資源



資料庫簡介

Lexicomp® 主介面

Lexicomp®

[Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

[Select Language](#) [Recent Documents](#)

[More Clinical Tools](#)

[Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#)

[Help](#)

臨床決策支援模組

主搜尋欄位

Lexicomp Online

Limit Search to

Enter drug, disease, or other keyword

Search

類別搜尋



Explore by General Category:

Drugs

Diseases

Toxicology

Patient Education

Laboratory

International Drugs

藥品名、疾病名、副作用、
使用禁忌、ATC Code 等

美國 FDA 新
藥核准通知

藥物特別警示

教育訓練影片
快速參考指引

New FDA Drug Approvals

Canagliflozin
Crofelemer
Lomitapide
Fluticasone and Vilanterol
Glycerol Phenylbutyrate

[More new FDA drug approvals](#)

Special Alerts

► Azithromycin (Systemic): Health Canada Issues Warning for Azithromycin Heart Risks
► Zolpidem: Zolpidem Label Changes
► Thalidomide: Health Canada Issues Notice Regarding the Development of Arterial Thromboembolic Events with the Use of Thalidomide
Levonorgestrel: FDA Approves Plan B® One Step Without a Prescription for Women 15 Years and Older
Ado-Trastuzumab Emtansine: Kadcyla™ Safety Alert

[More special alerts](#)



Training Videos



Quick Reference Guide

Wolters Kluwer
Health

[Terms & Conditions](#) // [Disclaimer](#)



Copyright 1978-2013 Lexicomp All Rights Reserved
1100 Terex Road | Hudson, OH 44236
Phone: 330.650.6506
Toll Free: 800.837.5394
International: +1.330.650.6506
Fax: 330.656.4307

各資料庫簡介

Lexicomp®

Enter drug, disease, or other keyword Search Limit Search to

Feedback Corporate User Guide Logout

Select Language Recent Documents

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology

各資料庫細部介紹

各資料庫簡介

Lexi-Drugs

All Databases

[FlySheet Demo](#)

[Lexi-Drugs](#)

Our most comprehensive drug database, Lexi-Drugs covers every patient population, as well as the following clinical specialties: Pharmacy, Nursing, Internal Medicine, Cardiology, Oncology, Psychiatry, Anesthesiology, and Dentistry. Independently rated as the #1 drug database for the PDA, Lexi-Drugs includes up to 86 fields of information, including Adverse Reactions, Canadian brand names, Dosing, FDA Special Alerts, Medication Safety Issues, Pharmacodynamics/Kinetics, and trade names from more than 100 countries.

[Pediatric and Neonatal Lexi-Drugs](#)

Specifically designed for Pediatricians, other clinicians who work with pediatric patients, or in any situation where pediatric dosing information is required, this database contains detailed guidelines that have been researched and compiled by pediatric specialists. It includes over 900 drugs, with monographs that cover up to 48 fields of information, including very detailed neonatal and pediatric dosing.

[AHFS Essentials \(Adult and Pediatric\)](#)

Derived from the more extensive and detailed *AHFS Drug Information*, the AHFS DI Essentials database provides a deeper level of actionable drug information and includes off-label uses. This database is ideal for more detailed questions at the point-of-care. The drug monograph content is derived from *AHFS Drug Information*, a premier source of meticulously evidence-based drug information. Includes information on safe drug use in pregnant and breast-feeding women, off label uses, and an overview of the drug's pharmacologic actions and effects.

[AHFS DI \(Adult and Pediatric\)](#)

This database provides the deepest level of drug information with off-label uses and recommendations from an authoritative source. A recognized Official Compendium by the US Congress, this is the only drug information resource published from a professional scientific association. Lexi-Comp ONLINE gives you the ability to search this database as well as link to this information directly from a Lexi-Comp or AHFS Essentials drug monograph.

[Martindale: The Complete Drug Reference](#)

Martindale is the industry's most reliable and respected international drug reference. Maintained with the same exceptional standards Lexi-Comp follows, *Martindale* provides an unbiased and thorough review of pharmaceutical products available worldwide. *Martindale* offers an unrivalled global focus on the identification of medications, local equivalents, manufacturers, and more.

[5-Minute Clinical Consult](#)

Based on the popular print title, this database provides comprehensive and structured information covering over 900 medical conditions, diseases, and procedures, as well as 30 treatment algorithms. Designed to provide access to diagnosis and treatment information, it's perfect for the busy practitioner, resident, or student.

[Lexi-Drugs International](#)

Lexi-Drugs International contains abbreviated monographs for drugs that are available outside of North America. The database is intended to provide a general overview of the use and pharmacologic classification of the drug, including basic information on dosing, dosage forms, and potential restrictions.

[Geriatric Lexi-Drugs](#)

This specialized database contains over 840 geriatric-sensitive drug monographs, supplying up to 31 key fields of information. Extensive information on drug interactions and drug dosing in the elderly and adult populations is included, as well as dosing adjustments for patients with renal/hepatic impairment. Special geriatric considerations are covered.

[Natural Products Database](#)

The natural product content is adapted from *The Review of Natural Products*, a Facts & Comparisons online database. Each monograph includes a Clinical Overview section and then additional in-depth fields that provide a detailed discussion of the use, dosing, adverse reactions, and interactions of each herbal product.

Generic Names
U.S. Brand Names
Canadian Brand Names
Charts/Special Topics
Changed Last 7 Days
Pharmacologic/Therapeutic Category
REMS
Prescribing and Access Restrictions
Black Box Warnings
Special Alerts

[Pediatric and Neonatal Lexi-Drugs](#)

Generic Names
U.S. Brand Names
Canadian Brand Names
Charts/Special Topics
Changed Last 7 Days
Pharmacologic/Therapeutic Category
REMS
Prescribing and Access Restrictions
Black Box Warnings
Special Alerts

[AHFS Essentials \(Adult and Pediatric\)](#)

Generic Names

online.lexi.com/lco/action/index/type/all

各資料庫詳細介紹

Lexicomp®

Enter drug, disease, or other keyword

Search

Limit Search to ▾

Interactions

Drug I.D.

Calculators

IV Compatibility ▾

Patient Education

Toxicology

Feedback

Corporate

User Guide

Logout

Select Language ▾

Recent Documents ▾

More Clinical Tools ▾

Available Indexes

Lexi-Drugs

Generic Names

U.S. Brand Names

Canadian Brand Names

Charts/Special Topics

Changed Last 7 Days

Pharmacologic/Therapeutic Category

REMS

Prescribing and Access Restrictions

Black Box Warnings

Special Alerts

Lexi-Drugs

Our most comprehensive drug database, Lexi-Drugs covers every patient population, as well as the following clinical specialties: Pharmacy, Nursing, Internal Medicine, Cardiology, Oncology, Psychiatry, Anesthesiology, and Dentistry. Independently rated as the [#1 drug database for the PDA](#), Lexi-Drugs includes up to 86 fields of information, including Adverse Reactions, Canadian brand names, Dosing, FDA Special Alerts, Medication Safety Issues, Pharmacodynamics/Kinetics, and trade names from more than 100 countries.

Description of Fields

Generic Name

U.S. or Canadian adopted name

ALERT: U.S. Boxed Warning

The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or [www.fda.gov](#).

Special Alerts

Important information (new warnings, adverse reactions, etc) to be conveyed to clinicians expeditiously

Drug Shortages

Contains links to information from ASHP and/or the FDA when a specific drug product may be in short supply or unavailable

Pronunciation

Phonetic pronunciation guide

Brand Names

Brand Names: U.S.

Trade names found in the United States (manufacturer-specific). The symbol [DSC] appears after trade names that have been recently discontinued.

Brand Names: Canada

Trade names found in Canada

Pharmacologic Category

Unique systematic classification of medications

Dosages

Dosing: Adult; Geriatric; Pediatric; Renal Impairment; Hepatic Impairment; Adjustment for Toxicity; Combination Regimens; Calculations

The amount of the drug to be typically given or taken during therapy for children and adults; also includes any dosing adjustments/comments for renal impairment or hepatic impairment and other suggested dosing adjustments (eg, hematological toxicity). Combination regimens identify how the drug may be used in combination with other agents for the treatment of neoplastic disease. Calculations relevant to dosing are also provided.

Uses

資料庫內含資料領域及介紹

Editorial Advisory Panel

Joseph F. Alexander, Jr., MD

Allergist/Immunologist, Summa Health System

William Alvarez Jr., BS, PharmD, BCPS

Pharmacotherapy Specialist, Lexi-Comp, Inc

Christina L. Aquilante, PharmD

Associate Professor, Department of Pharmaceutical Sciences, University of Colorado Denver School of Pharmacy

Verna L. Baughman, MD

Professor, Anesthesiology and Neurosurgery, University of Illinois

Judith L. Beizer, PharmD, CGP, FASCP

Clinical Professor, Department of Clinical Pharmacy Practice, St John's University College of Pharmacy and Health Sciences

Jeffrey R. Bishop, PharmD, MS, BCPP

Assistant Professor, Department of Pharmacy Practice, University of Illinois at Chicago

Mark F. Bonfiglio, BS, PharmD, RPh

VP, Drug Information Content, Lexi-Comp, Inc

Diedra L. Bragalone, PharmD, MBA, BCOP, BCPS

Pharmacotherapy Specialist, Lexi-Comp, Inc

Lee Bragg, PharmD

Pharmacotherapy Specialist, Lexi-Comp, Inc

Susan P. Bruce, PharmD, BCPS

Chair and Associate Professor, Department of Pharmacy Practice, Northeast Ohio Medical University (NEOMED)

Gretchen L. Brummel, PharmD, BCPS

Director, Clinical Pharmacy Services, Penn State Milton S. Hershey Medical Center

William F. Buss, PharmD

Clinical Pharmacist, Neonatal Intensive Care Unit, Indiana University Health, James Whitcomb Riley Hospital for Children

編輯群介紹

資料庫內容

- Lexi-Drugs
- Pediatric and Neonatal Lexi-Drugs
- AHFS Essentials
- AHFS DI
- Martindale
- 5-Minute Clinical Consult
- Lexi-Drugs International
- Geriatric Lexi-Drugs
- Natural Products Database
- Pharmacogenomics
- Infectious Diseases
- Lab Test and Diagnostic Procedures
- Lexi-Patient Education - Disease and Procedures (Multi Language)
- Lexi-Patient Education - Adult Medications (Multi Language*, Chinese)
- Lexi-Patient Education - Pediatric Medications (Multi Language*, Chinese)
- Lexi-Tox
- Drug Allergy and Idiosyncratic Reactions
- Pregnancy and Lactation, In-Depth
- Lexi-Interact
- US Drug Images
- IV Compatibility -King Guide

* 目前已支援多達 19 種語言

範例與討論

臨床情境 #1 - 問題產生

- 現在要開立 FOLFOX4 (Oxaliplatin + 5-FU + Leucovorin) 給大腸直腸癌病患，卻發現 Leucovorin 缺藥，請問有替代藥品或其他處理方式嗎？



臨床情境 #1 - 輸入檢索字詞

Lexicomp®

[Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

Select Language Recent Documents

More Clinical Tools

Lexicomp Online

Limit Search to

Leucovorin Search

- Leucovorin
- Leucovorin (AT, BG, CH, DE, GR, IE, IL, PL, TH, UY)
- Leucovorin Ca (PL)
- Leucovorin Calcium
- Leucovorin Calcium (AU, CZ, HK, HN, ID, IN, MY, NZ, TH)
- Leucovorin Calcium for Injection
- Leucovorin Calcium Injection
- Leucovorin calcium injection, 10mg/mL (CA)

Patient Education

Laboratory

International Drugs

New FDA Drug Approvals

Canagliflozin
Crofelemer
Lomitapide
Fluticasone and Vilanterol
Glycerol Phenylbutyrate

[More new FDA drug approvals](#)

Special Alerts

► Azithromycin (Systemic): Health Canada Issues Warning for

anges
ues Notice Regarding the Development
with the Use of Thalidomide
B® One Step Without a Prescription for
syla™ Safety Alert

1. 輸入藥名

- 自動完成功能
- 學名、商品名

2. 按下 Search

Wolters Kluwer
Health

[Terms & Conditions](#) // [Disclaimer](#)



Copyright 1978-2013 Lexicomp All Rights Reserved
1100 Terex Road | Hudson, OH 44236
Phone: 330.650.6506
Toll Free: 800.837.5394
International: +1.330.650.6506
Fax: 330.656.4307

臨床情境 #1 - 選擇資料庫

Lexicomp®

Enter drug, disease, or other keyword Limit Search to ▾

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education

Search Results : Monograph name beginning with "

All Results

FlySheet Demo
No occurrences

Lexi-Drugs
[Leucovorin Calcium](#) Updated 5/23/13

Pediatric and Neonatal Lexi-Drugs
[Leucovorin Calcium](#) Updated 5/23/13

AHFS Essentials (Adult and Pediatric)
[Leucovorin Calcium](#) Updated 4/2/13

AHFS DI (Adult and Pediatric)
[Leucovorin Calcium](#) Updated 4/2/13



Martindale: The Complete Drug Reference
[Leucovorin Calcium Injection USP 36](#) Updated 4/24/13
[Leucovorin Calcium Tablets USP 36](#) Updated 4/24/13
[Leucovorin Calcium](#) Synonym for Calcium Folate Updated 4/24/13
[Leucovorin](#) Synonym for Folinic Acid Updated 4/24/13

Patient Education - Adult Medication
[Leucovorin Calcium](#) Updated 5/1/13

Patient Education - Pediatric Medication
[Leucovorin Calcium](#) Updated 4/10/13

Lexi-Tox
[Leucovorin Calcium \[ANTIDOTE\]](#) Updated 5/23/13

[Terms & Conditions](#) // [Disclaimer](#)

Copyright 1978-2013 Lexicomp All Rights Reserved
1100 Terex Road | Hudson, OH 44236
Phone: 330.650.6506
Toll Free: 800.837.5394
International: +1.330.650.6506
Fax: 330.656.4307

- 搜尋結果將依資料庫分類條列
 - Lexi-Drugs
 - Pediatric Lexi-Drugs
 - AHFS Essentials
 - AHFS Drug Info
 - Martindale
 - Patient Education
 - Lexi-Tox
 - Harrison's Practice
 - Lexi-Drugs International
 - Geriatric Lexi-Drugs
 - Natural Products
 - Pharmacogenomics
 - Infectious Diseases
 - Lab Tests/Diagnostic Procedures

資料庫定期更新並標註更新日期

Feedback Corporate User Guide Logout

Select Language ▾ Recent Documents ▾

More Clinical Tools ▾

Filter Results ▾ [Print](#) [Help](#)

Jump to field
[Administration: I.V.](#)
[Administration: Injectable Detail](#)
[Administration: Oral](#)
[Adverse Reactions](#)
[Anatomic Therapeutic Chemical \(ATC\) Classification](#)
[Brand Names: Canada](#)
[Breast-Feeding Considerations](#)
[Calculations](#)
[Clinical Practice Guidelines](#)
[Compatibility](#)
[Contraindications](#)
[Dietary Considerations](#)
[Dosage Forms](#)
[Dosing: Adult](#)
[Dosing: Combination Regimens](#)
[Dosing: Geriatric](#)
[Dosing: Hepatic Impairment](#)
[Dosing: Pediatric](#)
[Dosing: Renal Impairment](#)
[Drug Interactions](#)
[Drug Shortages](#)
[Effects on Bleeding](#)
[Effects on Dental Treatment](#)
[Extemporaneously Prepared](#)
[Generic Available \(U.S.\)](#)
[Index Terms](#)
[International Brand Names](#)
[Lactation](#)
[Local Anesthetic/Vasoconstrictor Precautions](#)
[Mechanism of Action](#)
[Medication Safety Issues](#)
[Mental Health: Effects on Mental Status](#)
[Mental Health: Effects on Psychiatric Treatment](#)
[Metabolism/Transport Effects](#)

直接瀏覽特定段落

臨床情境 #1 - 瀏覽資料

Lexicomp®

Enter drug, disease, or other keyword Limit Search to

Feedback Corporate User Guide Logout

Select Language Recent Documents

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology More Clinical Tools

Leucovorin Calcium (Lexi-Drugs)

Navigation Tree


- Drug Shortages
- Pronunciation
- Brand Names
- Pharmacologic Category
- Dosages
- Uses
- Clinical Practice Guidelines
- Administration and Storage
- Issues
- Medication Safety Issues
- Warnings & Precautions
- Pregnancy & Lactation
- Adverse Reactions
- Interactions
- Patient & Therapy Management
- Preparations
- Pharmacology & Pharmacokinetics
- Dental Information
- Pearls & Related Information
- Index Terms
- References
- International Brand Names

Expand All

Monograph Images Adult Patient Education Pediatric Patient Education

Leucovorin Calcium (Lexi-Drugs)

Drug Shortages One or more forms of this drug may be in short supply or unavailable. Refer to the following for additional information:
ASHP: <http://www.ashp.org/menu/DrugShortages>
FDA: <http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314741.htm#leucovorin>

Pronunciation

(too koe VOR in KAL see um)

Brand Names: Canada Lederle Leucovorin

Pharmacologic Category Antidote, **Chemotherapy Modulating Agent**, Rescue Agent (Chemotherapy); Vitamin, Water Soluble

Dosing: Adult
Treatment of weak folic acid antagonist overdosage (eg, trimethoprim, pyrimethamine): Oral: 5-15 mg/day
Folate-deficient megaloblastic anemia: I.M.: ≤1 mg/day
High-dose methotrexate-rescue dose: Initial: Oral, I.M., I.V.: 15 mg (~10 mg/m²); start 24 hours
Normal methotrexate elimination: Oral, I.M., I.V.: 15 mg every 6 hours
Delayed early methotrexate elimination: I.V.: 150 mg every 3 hours until methotrexate level is < 0.1 mg/m²
Colorectal cancer (also refer to Combination Regimens):
I.V.: 200 mg/m² over at least 3 minutes (used in combination with fluorouracil 370 mg/m²)
or
I.V.: 20 mg/m² (used in combination with fluorouracil 425 mg/m²)
Methotrexate overdose: Note: The amount of leucovorin administered should equal the amount of methotrexate administered.
I.V.: 1 mg per mg of methotrexate inadvertently administered; 100-1000 mg/m² every 3-6 hours (ascites, pleural effusion)
A nomogram for leucovorin rescue in cancer patients receiving high-dose methotrexate based on methotrexate level:
≥80 micromole/L: 1000 mg/m² every 6 hours
≥8 to <80 micromole/L: 100 mg/m² every 3 hours
≥2 to <8 micromole/L: 10 mg/m² every 3 hours
≥0.1 to <2 micromole/L: 10 mg/m² every 6 hours
Use of I.T. leucovorin is not advised (Jardine, 1996; Smith, 2008).

Search Results : Pharmacologic category is "Chemotherapy Modulating Agent"

All Results

FlySheet Demo
No occurrences

Lexi-Drugs
[Leucovorin Calcium](#) Updated 5/23/13
[LEVOleucovorin](#) Updated 5/20/13

LEVOleucovorin

臨床情境 #1 - 尋找答案

Alternative Agents & Management

ASHP 建議作法


- Reserve folinic acid products (racemic leucovorin, levoleucovorin (Fusilev)) for oncology patients receiving chemotherapy and patients with inadvertent folic acid antagonist overdose.¹⁰⁻¹²
- Folic acid is not an alternative for oncology uses or for folic acid antagonist overdose. Use folic acid for patients with megaloblastic anemias due to folic acid deficiency.¹³
- Reserve injectable folinic acid products for use in patients with colorectal cancer receiving combination therapy with fluorouracil.¹⁰⁻¹² Oral therapy has been evaluated in this setting,¹⁷ but may be less practical because of the large number of tablets required. Consider use of lower-dose injectable folinic acid regimens in patients with colorectal cancer when possible.^{18,19} If folinic acid injectable products are not available, treatment with fluorouracil alone may be considered and may allow for use of slightly higher fluorouracil doses (~10%) in patients with colorectal cancer as tolerated.^{18,19}
- Use oral leucovorin whenever possible for methotrexate rescue in osteogenic sarcoma, to reduce toxicity in patients with impaired methotrexate elimination, and to reduce toxicity after inadvertent folic acid antagonist overdose. However, injectable folinic acid products may be necessary when oral therapy is not an option in these patients (e.g., swallowing difficulty, gastrointestinal absorption problems).¹⁰⁻¹²
- The [Table](#) lists potential alternatives for folinic acid products.

臨床情境 #2 - 問題產生

- 王爺爺，75 歲、165 cm / 65 kg，懷疑人工關節感染。
- 醫師開立 Daptomycin (Cubicin®) 來控制感染情形。查房時護理師詢問 Daptomycin 可否用 D5W 稀釋給藥？此外，病人還有使用抗生素 Ertapenem (Invanz®)，這兩種抗生素是否可以同時滴注？



臨床情境 #2 - 選擇檢索工具



Lexicomp®

Interactions Drug I.D. Calculators **I.V. Compatibility** Patient Education Toxicology

Lexicomp Online

- 參考 King Guide to Parenteral Admixtures
- 查詢藥品之間是否相容、列舉與藥品相容之 Solution

■ Toxicology
■ Patient Education
■ Laboratory
■ International Drugs

臨床情境 #2 - 輸入檢索字詞

New Search	Appendix/Help	Feedback	Logout
<p>Welcome to the New King Guide. Use it on your Desktop, Tablet or Phone. Just in case, click to return to the old more familiar interface.</p>			
<p>Search IV Drugs (up to 10):</p>			
<div><input type="text" value="dap"/> ×</div>			
<p>Type DAPTOMYCIN</p>			

臨床情境 #2 - 尋找答案

DAPTOMYCIN

Search for another drug to view drug/drug compatibility with DAPTOMYCIN.

Y-SITE
Click to view drugs... **4 Drugs**

SYRINGE
Click to view drugs... **1 Drug**

ADMIXTURE
Click to view drugs... **9 Drugs**

DAPTOMYCIN

AKA: CUBUCIN®.

DESCRIPTION

U	D	D	D	D	D				
N	S	S	S	S	S	D	L	R	N S
S	P	W	W	R	S	S	R	R	S L
									C

Daptomycin for injection is a sterile, preservative-free, pale yellow to light brown, lyophilized cake containing approximately 900 mg/g of daptomycin for intravenous use following reconstitution with NS. The reconstituted solution is pale yellow to light brown, and should be diluted with NS prior to infusion (1934). - [1934](#)

STABILITY

U	D	D	D	D	D				
N	S	S	S	S	S	D	L	R	N S
S	P	W	W	R	S	S	R	R	S L
		X	X	X	X	X	X	C	C

Reconstituted solution is stable in the vial for 12 hours at room temperature or up to 48 hours if stored at 2-8°. The diluted solution is stable in the infusion bag for 12 hours at room temperature or 48 hours if refrigerated. The combined time (vial and infusion bag) at room temperature should not exceed 12 hours; the combined time (vial and infusion bag) should not exceed 48 hours. Daptomycin is compatible with NS and LR, but not with dextrose-containing diluents (1934). - [1934](#)

臨床情境 #2 - 圖示說明





[Back](#) **Appendix/Help**

Appendix 1 (Fluids A-H)




Appendix 2 (Abbo-Vac Solutions)

Infusion Fluid Abbreviations

Compatibility Symbols

The special grid included on monograph pages allows for quick reporting of compatibility , incompatibility , or conflicting data . In some instances conflicting results have been reported in the literature for a particular admixture. These contradictory reports are noted with a , and are described in the written entries.

NOTE:
Absence of a notation in the grid does not imply that the combination is compatible. Rather, it means that no information has been reported for that particular combination. The presence of other symbols in the grid, such as # and *, are included to help the reader locate the specific written entry about the drug combination, and the reference that pertains to that entry.

Symbol	Definition
	Incompatible
	Compatible
	Conflicting Reports
NA or blank	No Information Available (do not mix)

Types of Incompatibility

Conflicting Reports

Compatibility of Multiple Drug Admixtures

Frequently Asked Questions

臨床情境 #2 - Y-Site 相容表

DAPTOMYCIN

AKA: CUBUCIN®,

Y-SITE COMPATIBILITY TABLE	U N S P	D S W	D 1 0 W	D S L R	D S ¼ S	D S ½ S	D S N S	D S R	L R	R	N S	S L
CASPOFUNGIN ACETATE											C	
DORIPENEM											C	
ERTAPENEM											C	
SODIUM CITRATE	C											

臨床情境 #2 - 兩種以上藥物混合

[New Search](#)[Appendix/Help](#)[Feedback](#)[Logout](#)

Welcome to the New King Guide. Use it on your Desktop, Tablet or Phone. Just in case, [click to return to the old more familiar interface.](#)

Search IV Drugs (up to 10):

Search for another drug to view multiple drug compatibility results.

Click any drug to remove it from the results.

DAPTOMYCIN

ERTAPENEM

DAPTOMYCIN
Combined with:
ERTAPENEM

Y-Site

U		D	D	D	D	D				
N	D	1	5	5	5	5	D			
S	5	0	L	¼	½	N	5	L		N
P	W	W	R	S	S	S	R	R	R	S
										L

REFERENCES

2187 - Crabtree, A., Jefferson General Hospital, Port Townsend WA, personal communication (March 2010).

Daptomycin, 500 mg in 100 ml NS, and ertapenem, 1 gm in 50 ml NS, infused via Y-site, appeared physically compatible (2187).

Syringe
No other information available.

Admixture
No other information available.

臨床情境 #2 - 參考文獻

Lexicomp®

Enter drug, disease, or other keyword Limit Search to Select Language Recent Documents

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology More Clinical Tools

DAPTOmycin (Lexi-Drugs)

Navigation Tree

- Pronunciation
- Brand Names
- Pharmacologic Category
- Dosages
- Uses**
- Clinical Practice Guidelines
- Administration and Storage Issues
- Medication Safety Issues
- Warnings & Precautions
- Pregnancy & Lactation
- Adverse Reactions
- Interactions
- Patient & Therapy Management
- Preparations
- Pharmacology & Pharmacokinetics
- Dental Information
- Pearls & Related Information
- Index Terms

Monograph Images Adult Patient Education Pediatric Patient Education

Clinical Practice Guidelines

Diabetic Foot Infection:

IDSA, "The Diagnosis and Treatment of Diabetic Foot Infections," [2012](#)

Infective Endocarditis:

"AHA 2007 Guidelines for the Prevention of Infective Endocarditis," [April 2007](#)

British Society for Antimicrobial Chemotherapy (BSAC), "Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults," [2012](#)

Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infections:

Infectious Diseases Society of America, "Practice Guidelines for the Treatment of Methicillin-Resistant *Staphylococcus aureus*," [February 2011](#)

Prosthetic Joint Infection:

IDSA, "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline," [January 2013](#)

Administration: I.V. May administer I.V. push over 2 minutes or infuse IVPB over 30 minutes. Do not use in conjunction with ReadyMED® elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) leaching from the pump system into the daptomycin solution.

Storage Store under refrigeration at 2°C to 8°C (36°F to 46°F). Intact vials may be stored at room temperature for up to 12 months (data on file [Cubist Pharmaceuticals, 2011]). However, the manufacturer recommends storage under refrigeration. Room temperature stability information should only be utilized in situations where the drug has been inadvertently exposed to prolonged room temperature.

臨床情境 #3 - 產生問題

- 林伯伯，60 歲，過去病史為急性骨髓性白血病，因感染及呼吸衰竭而住進內科加護病房。護理師詢問是否要調整給藥？



- 目前給藥：
 - Fentanyl (cIF), Lorazepam (cIF), Norepinephrine (cIF), Dopamine (cIF), Imipenem/Cilastatin (IF), Vancomycin (IF), Amphotericin B (IF)
- IV Sets:
 - 3 way Central Venous Catheter x 1 + Cath x 1

臨床情境 #3 - 兩種以上藥物混合

Search IV Drugs (up to 10):

Search for another drug to add it to the multiple drug compatibility results.

Click any drug to remove it from the results.

C=Compatible
 X=Incompatible
 Ø=Conflicting Reports
 NA=No Data

Click any symbol to view the fluids, dosages, and details.
Click any drug to view the complete monograph for that drug.

FENTANYL CITRATE ✕

LORAZEPAM ✕

DOPAMINE HYDROCHLORIDE ✕

IMIPENEM-CILASTATIN SODI... ✕

VANCOMYCIN HYDROCHLO... ✕

Y-Site	AMPHOTER... B CHOLE...	DOPAMINE... HYDROCH...	FENTANYL... CITRATE...	IMIPENEM... SODIUM...	LORAZEPA...	NOREPINE... BITARTR...	VANCOMYC... HYDROCH...
AMPHOTERICIN B	-	X	C	X	C	NA	X
CHOLESTERYL							
SULFATE							
COMPLEX							
DOPAMINE	X	-		NA	C	C	C
HYDROCHLORIDE							
FENTANYL	C	C		NA	C	C	C
CITRATE							
IMIPENEM-	X			-	X	NA	NA
CILASTATIN							
SODIUM							
LORAZEPAM					-	C	C
					C	-	NA
					C	NA	-

	LORAZEPA...	NOREPINE... BITARTR...	VANCOMYC... HYDROCH...
SULFATE	NA	NA	NA
COMPLEX			
DOPAMINE	NA	-	NA
HYDROCHLORIDE			
FENTANYL	NA	NA	-
CITRATE			
IMIPENEM-	NA	NA	-
CILASTATIN			
SODIUM			
LORAZEPAM	NA	NA	NA
NOREPINEPHRINE	NA	C	NA
BITARTRATE			
VANCOMYCIN	NA	NA	NA
HYDROCHLORIDE			

Amphotericin B 與 Imipenem 不相容

點擊圖示瀏覽參考文獻、資料

臨床情境 #3 - 參考文獻

IMIPENEM-CILASTATIN SODIUM

AKA: PRIMAXIN®

**AMPHOTERICIN B CHOLESTERYL
SULFATE COMPLEX**

Y-Site

[illegible]

Amphotericin B cholesteryl sulfate complex, 0.83 mg/ml in D5W, and imipenem-cilastatin, 10 mg/ml in NS, mixed 1:1 using a simulated Y-site technique, resulted in gross precipitation within 4 hours at 23°C (1610).

Syringe

No other information available.

Admixture

No other information available.

REFERENCES

1610 - Trissel, L.A., et al., Hosp. Pharm. 33, 284 (1998).

臨床情境 #4 - 產生問題

- 翁先生，有癲癇的病史，長期使用抗癲癇藥物 Valproic Acid，控制良好 (Valproic Acid level = 50mg/L)。
- 此次因嚴重感染而插管進入加護病房，並使用 Meropenem 來控制感染，入住的隔天發生新的癲癇，Valproic Acid level = 5mg/L。
- 會是什麼原因導致 Valproic Acid 濃度降低？

臨床情境 #4 - 選擇檢索工具


Lexicomp®

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology

Lexicomp Online

Limit Search to ▾

Enter drug, disease, or other keyword

 Explore by General Category:

- ☐ Drugs
- ☐ Diseases
- ☐ Toxicology
- ☐ Patient Education
- ☐ Laboratory
- ☐ International Drugs

臨床情境 #4 - 輸入檢索字詞

Lexicomp®
 Search Limit Search to ▼

[Home](#) [Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility ▼](#) [Patient Education](#) [Toxicology](#)

Interactions

Selected Items

Selected Items
None

Analyze **Clear**

Search
Search Interact
 Search

Important Product Information
Interactions DOES NOT address chemical compatibility related to I.V. dru
more I.V. drugs together in the same container, or running them together throug
available to Institutional clients and others as an add-on from the main Lexicom

臨床情境 #4 - 輸入檢索字詞

Lexicomp®
 Search Limit Search to ▾

[Home](#) [Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility ▾](#) [Patient Education](#) [Toxicology](#)

Interactions

Selected Items

Selected Items
None

Analyze **Clear**

Search

Search Interact
 Search
Valproic Acid and Derivatives

Important Product Information
Interactions DOES NOT address chemical compatibility related to I.V. dru
more I.V. drugs together in the same container, or running them together throug
available to Institutional clients and others as an add-on from the main Lexicom

臨床情境 #4 - 藥物交互作用比對結果

Lexicomp®

Enter drug, disease, or other keyword Limit Search to

[Home](#) [Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#)

Interactions

Selected Items

☒ [Meropenem](#)

☒ [Valproic Acid and Derivatives](#)

Search Interaction A

Lexicomp Interactions

View interaction detail by [link](#).

Meropenem

- D** [Valproic Acid and Derivatives](#)

Valproic Acid and Derivatives

- D** [Meropenem \(Carbapenems\)](#)

Created on 2013/10/10 下午 08:05:22

Disclaimer: Readers are advised that decisions regarding drug therapy

• Risk Rating 為 D 級

臨床情境 #4 - Risk Rating 參考表

Risk Rating	Action	Description
A	No Known Interaction	Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions between the specified agents
B	No Action Needed	Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern resulting from their concomitant use.
C	Monitor Therapy	Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these two medications usually outweigh the risks. An appropriate monitoring plan should be implemented to identify potential negative effects. Dosage adjustments of one or both agents may be needed in a minority of patients.
D	Consider Therapy Modification	Data demonstrate that the two medications may interact with each other in a clinically significant manner. A patient-specific assessment must be conducted to determine whether the benefits of concomitant therapy outweigh the risks. Specific actions must be taken in order to realize the benefits and/or minimize the toxicity resulting from concomitant use of the agents. These actions may include aggressive monitoring, empiric dosage changes, choosing alternative agents.
X	Avoid Combination	Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The risks associated with concomitant use of these agents usually outweigh the benefits. These agents are generally considered contraindicated.

臨床情境 #4 - 參考檢索結果

Search

Interaction Analysis

Interaction Monograph

Print

Help

Risk Rating D: Consider therapy modification

Summary Carbapenems may decrease the serum concentration of Valproic Acid and Derivatives. **Severity** Major **Reliability Rating** Fair

Patient Management Concurrent use of carbapenem antibiotics with valproate products is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication. Close monitoring of valproate concentrations is necessary whenever using a carbapenem with valproic acid and derivatives (particularly when starting or stopping the carbapenem). Valproate concentrations may decrease significantly with addition of a carbapenem, and increased doses may not be able to adequately compensate for the interaction. Valproate concentrations generally return towards normal shortly after discontinuation of the carbapenem.

Carbapenems Interacting Members Doripenem*; Ertapenem*; Imipenem*; Meropenem*

* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.

Discussion Several case reports and case series describe significant decreases in serum valproate concentrations (usually to subtherapeutic values) following the initiation of therapy with a carbapenem antibiotic.^{1,2,3,4,5,6,7} In these cases, serum valproate concentrations decreased rapidly (often within days) and substantially following carbapenem initiation, and valproate concentrations generally returned to normal in a similarly rapid fashion. Seizures accompanied some, but not all, of the pharmacokinetic changes.

The mean valproate AUC was reduced by an average of 63% with concurrent doripenem in a study of 23 healthy volunteers who received doripenem (500 mg every 8 hrs x 4 doses) plus valproic acid (500 mg every 12 hrs x 7 days).⁸ Valproate maximum serum concentrations (C_{max}) and minimum serum concentrations (C_{min}) were similarly decreased (by an average of 45% and 78%, respectively) with concurrent doripenem. Concentrations of the valproate glucuronide metabolite were increased with doripenem.

The mechanism(s) responsible for this observed interaction is unclear, but decreased enteric hydrolysis of the valproate glucuronide (i.e., decreased enterohepatic recirculation) is thought to be principally responsible.^{8,9,10,11,12,13,14} Other possible mechanisms include decreased intestinal absorption,^{15,16} increased valproate glucuronidation,¹³ increased renal clearance of valproate glucuronide,^{14,17} and increased distribution of valproate into red blood cells.⁷

Of note one case study describes coadministration of meropenem and valproic acid for 13 days with no apparent interaction in a cirrhotic patient.¹⁸ The reason for an absent interaction in this case is uncertain, though it is possible that impaired hepatic glucuronidation and biliary drug secretion due to the patient's advanced liver disease led to decreased valproic acid clearance, countering the effects of the carbapenem.

Footnotes

1. Nagai K, Shimizu T, Togo A, et al, "Decrease in Serum Levels of Valproic Acid During Treatment with a New Carbapenem, Panipenem/Betamipron," *J Antimicrob Chemother*, 1997, 39(2):295-6. [[PubMed 9069562](#)]

2. Yamanata T, Momoi MY, Murai K, et al, "Panipenem/Betamipron and Decreases in Serum Valproic Acid Concentration," *Ther Drug Monit*, 1998, 20(4):396-400. [[PubMed](#)]

臨床情境 #5 - 產生問題

- 陳爺爺，80 歲，170 cm / 75 kg，Cr 0.8 mg/dl，懷疑為院內肺炎感染。
- 醫師想開立 Imipenem 和 Amikacin 經驗性使用，來電詢問 Amikacin 之使用劑量？

臨床情境 #5 - 選擇檢索工具


Lexicomp®

Interactions Drug I.D. **Calculators** I.V. Compatibility Patient Education Toxicology

Lexicomp Online

Limit Search to ▾

Enter drug, disease, or other keyword **Search**


 Explore by General Category:

- Drugs
- Diseases
- Toxicology
- Patient Education
- Laboratory
- International Drugs

臨床情境 #5 - 常用計算工具

- Absolute Neutrophil Count
- Apgar Score
- Calcium Correction in Hypoalbuminemia
- CHA₂DS₂-VASc Score
- Child Pugh Classification
- Creatinine Clearance by Cockcroft-Gault
- Glomerular Filtration Rate by MDRD
- Glomerular Filtration Rate by Schwartz (兒童劑量)
- HAS-BLED Bleeding Risk Score
- TIMI Risk Score (STEMI)

臨床情境 #5 - 選擇計算工具



Lexicomp®

Enter drug, disease, or other keyword

Interactions Drug I.D. Calculators I.V. Compatibility

Calculators

Calculator Controls

Calculator Lookup

Browse Category

All

Browse Results

- A-a Gradient
- ANC: Absolute Neutrophil Count
- APACHE II Score
- Abciximab
- Acetylcysteine
- Adjusted Body Weight
- Advanced Life Support: Adult
- Advanced Life Support: Neonatal
- Advanced Life Support: Pediatric
- Aminoglycosides: Dosing by Serum Levels
- Aminoglycosides: Empiric Dosing
- Aminoglycosides: Extended, Initial Dose
- Aminoglycosides: Extended, Interval Adjust
- Amiodarone

- 藥學相關計算式
 1. 常用計算式 BMI, BSA, eGFR...
 2. 劑量換算 Corticosteroid, EPO, Fentanyl...
 3. 藥物動力學 Aminoglycoside, Vancomycin, Phenytoin...
 4. 藥品輸注速率 Propofol, Nitroglycerin, Dopamine...
 5. 藥品劑量計算 Carboplatin
 6. 毒物

臨床情境 #5 - 輸入計算值

Lexicomp® [Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

Enter drug, disease, or other keyword [Search](#) Limit Search to [Select Language](#) [Recent Documents](#)

[Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#) [More Clinical Tools](#)

Calculators

Calculator Controls

Calculator Lookup

[Search](#)

Browse Category

General [Show All](#)

Browse Results

- A-a Gradient
- ANC: Absolute Neutrophil Count
- APACHE II Score
- Abciximab
- Adjusted Body Weight
- Advanced Life Support: Adult
- Advanced Life Support: Neonatal
- Advanced Life Support: Pediatric
- Anion Gap
- Body Mass Index
- Body Surface Area: Adult
- Body Surface Area: Pediatric
- Calcium Correction
- Calvert Formula (CARBOplatin Dosing)
- Creatinine Clearance: Adult

Calculator

Aminoglycosides: Empiric Dosing

[Print](#) [Help](#)


Drug	Amikacin	
Age	80	years
Gender	male	
Weight	75	kg
Height	170	cm
Cl _{Cr} Method	Cockcroft-Gault	
SrCr	0.8	mg/dL
Desired Peak (C _{dp})	20	mcg/mL
Desired Trough (C _{dtr})	3	mcg/mL
Vol of Dist. (V _d)	0.25 L/kg	
Detail	Hide	

[Calculate](#) [Reset](#)

Suggested Loading Dose (LD)	325	mg
Suggested Maintenance Dose (MD)	300	mg
Suggested Interval (tau)	8	hrs
Predicted Peak (C _{pp})	20	mcg/mL
Predicted Trough (C _{ptr})	3.2	mcg/mL

臨床情境 #6 - 產生問題

- 邱小弟，4 歲，Acute Lymphoblastic Leukemia, Precursor T-cell Type, VHR。
- 自 4/25 晚上起開始說不出話，當想說話時只能大哭，這跟他的藥品使用有相關嗎？
- 用藥
 - Etoposide 61 mg IVA on 4/15 - 4/19
 - Cylophosphamide 268 mg IVA on 4/15 - 4/19
 - Nelarabine 394 mg IVA on 4/24 - 4/28
 - Allopurinol 0.5 tab bid on 4/14 - 4/28
 - Ciprofloxacin 0.5 tab qd on 4/15 - 4/22



臨床情境 #6 - 輸入檢索字詞並限制條件

Lexicomp®

Feedback Corporate User Guide Logout

Select Language Recent Documents

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology More Clinical Tools

Lexicomp Online

speech order

Limit Search to

- Monograph Name
- Adverse Reactions
- Contraindications
- Charts/Special Topics
- Drug Interactions
- Use
- Warnings/Precautions
- NDC
- Methodology
- Pharmacologic Category
- Field Name
- Manufacturer
- All Text

Search

adverse reactions

New FDA Drug Approvals

- Canagliflozin
- Crofelemer
- Lomitapide
- Fluticasone and Vilanterol
- Glycerol Phenylbutyrate

[More new FDA drug approvals](#)

Special Alerts

- ▶ Azithromycin (Systemic): Health Canada Issues Warning for Azithromycin Heart Risks
- ▶ Zolpidem: Zolpidem Label Changes
- ▶ Thalidomide: Thalidomide Associated With Increased Risk Of Second Primary Malignancy, Health Canada Issues Alert-May 2013
- ▶ Thalidomide: Health Canada Issues Notice Regarding the Development of Arterial Thromboembolic Events with the Use of Thalidomide

Levonorgestrel: FDA Approves Plan B® One Step Without a Prescription for Women 15 Years and Older

[More special alerts](#)

Training Videos

Quick Reference Guide

online.lexi.com/lco/action/home#

臨床情境 #6 - 尋找答案

Lexicomp® [Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

Enter drug, disease, or other keyword Limit Search to

Select Language Recent Documents

[Home](#) [Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#) [More Clinical Tools](#)

Search Results : "speech disorder" in Adverse Reactions

All Results

[ClomiPRAMINE](#) Updated 5/20/13
[Dexmedetomidine](#) Updated 5/20/13
[Diatrizoate Meglumine](#) Updated 5/20/13
[Dicyclomine](#) Updated 5/20/13
[Eletriptan](#) Updated 5/20/13
[FentaNYL](#) Updated 5/20/13
[Flupentixol](#) Updated 5/20/13
[Frovatriptan](#) Updated 5/20/13
[Gadopentetate D](#) Updated 5/20/13
[Glatiramer Acete](#) Updated 5/20/13
[Hyoscyamine](#) Updated 5/20/13
[Interferon Alfacon](#) Updated 5/20/13
[Iopromide](#) Updated 5/20/13
[Lansoprazole](#) Updated 5/20/13
[Nabilone](#) Updated 5/20/13
[Nalbuphine](#) Updated 5/20/13
[Nelarabine](#) Updated 5/20/13
[OnabotulinumtoxinA](#) Updated 5/20/13
[OXcarbazepine](#) Updated 5/20/13
[OxyCODONE](#) Updated 5/20/13
[Pilocarpine \(Systemic\)](#) Updated 5/20/13
[Pimozide](#) Updated 5/20/13
[Pregabalin](#) Updated 5/20/13
[Quazepam](#) Updated 5/20/13
[RisperiDONE](#) Updated 5/20/13
[Saquinavir](#) Updated 5/20/13
[TiaGABine](#) Updated 5/20/13

1% to 10%:

Cardiovascular: Hypotension (8%), sinus tachycardia (8%), chest pain (5%)

Central nervous system: Ataxia (2% to 9%; grades 2/3: children 1%, adults 8%), confusion (8%), insomnia (7%), depressed level of consciousness (6%; grades 2-4: 2%), depression (6%), seizure (grade 3: 1% adults; grade 4: 6% children), motor dysfunction (4%; grades 2/3: 2%), amnesia (3%; grade 2: 1%), balance disorder (2%; grade 2: 1%), sensory loss (1% to 2%), aphasia (grade 3: 1%), attention disturbance (1%), cerebral hemorrhage (grade 4: 1%), coma (grade 4: 1%), encephalopathy (grade 4: 1%), hemiparesis (grade 3: 1%), hydrocephalus (1%), intracranial hemorrhage (grade 4: 1%), lethargy (1%), leukoencephalopathy (grade 4: 1%), loss of consciousness (grade 3: 1%), mental impairment (1%), nerve paralysis (1%), neuropathic pain (1%), nerve palsy (1%), paralysis (1%), sciatica (1%), sensory disturbance (1%), **speech disorder (1%)**

臨床情境 #7 - 產生問題

- 呂爺爺，75 歲，有顱內出血病史，長期使用 Valproic Acid、Topiramate、Acetazolamide 等藥物控制。
- 此次因呼吸衰竭而插管住院，實驗室檢查發現病人有代謝性酸中毒 (Metabolic Acidosis) 現象，排除其他常見原因後懷疑是藥物引起，醫師詢問可能是何種藥物？



臨床情境 #7 - 輸入檢索字詞並限制條件

Home Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology

Lexicomp Online

Adverse Reactions ▾

Metabolic Acidosis

Monograph Name

Adverse Reactions

Contraindications

Charts/Special Topics

Drug Interactions

Use

Warnings/Precautions

NDC

Methodology

Pharmacologic Category

Field Name

Manufacturer

All Text

Search

adversereactions

Explore

- Drug
- Disease
- Toxicology
- Patient Education
- Laboratory
- Interactions

臨床情境 #7 - 尋找答案

Lexicomp®

Adverse Reactions Adverse events are reported for placebo-controlled trials of adjunctive therapy in adult and pediatric patients. Unless otherwise noted, the percentages refer to incidence in epilepsy trials. **Note:** A wide range of dosages were studied; incidence of adverse events was frequently lower in the pediatric population studied.

>10%:

Central nervous system: Somnolence (15% to 29%), dizziness (4% to 25%; dose dependent), fatigue (9% to 16%; dose-dependent), nervousness (9% to 18%), ataxia (6% to 16%), psychomotor slowing (3% to 13%; dose dependent), speech problems (2% to 13%), memory difficulties (2% to 12%), behavior problems (children 11%), confusion (4% to 11%)

Endocrine & metabolic: Serum bicarbonate decreased (dose related: 7% to 67%; marked reductions [to <17 mEq/L] 1% to 11%)

Gastrointestinal: Anorexia (4% to 24%; dose dependent), nausea (6% to 10%; migraine trial: 9% to 14%)

Neuromuscular & skeletal: Paresthesia (1% to 11%; migraine trial: 35% to 51%)

Ocular: Abnormal vision (2% to 13%)

Respiratory: Upper respiratory infection (migraine trial: 12% to 14%)

Miscellaneous: Injury (14%)

[Teniposide](#) Updated 10/4/13
[Tinzaparin](#) Updated 10/7/13
[Topiramate](#) Updated 10/7/13
[Total Parenteral Nutrition](#) Updated 8/19/13
[Zonisamide](#) Updated 10/4/13

臨床情境 #8 - 產生問題

- 47 歲的柯小姐患有精神分裂症，此次因吞服約 100 顆 Norvasc® (AmLODIPine) 企圖自殺而住進加護病房觀察。此時該如何處理 Calcium Channel Blocker 中毒？

臨床情境 #8 - 輸入檢索字詞

Lexicomp®

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology

Lexicomp Online

Limit Search to

Calcium Channel Blocker Search

1. 輸入中毒原因
2. 按下 Search

Explore by General Category:

- Drugs
- Diseases
- Toxicology
- Patient Education
- Laboratory
- International Drugs

臨床情境 #8 - 參考臨床指引

Lexicomp®

Treatment: Stabilization Initially evaluate and correct immediate life-threatening complications (eg, airway, breathing, and circulation). The most common serious complications are hypotension and bradycardia. Laryngoscopy may induce a vagal response; may administer atropine prior to intubation.

Treatment: Decontamination **Ingestion:** If the patient presents within 1 hour of ingestion, consider the following decontamination procedure(s):

- Gastric lavage: In rare situations when gastric lavage is deemed appropriate, it is most effective if initiated within 1 hour of the ingestion; however, gastric lavage has not been proven to be beneficial and is not routinely recommended due to the risk of complications and the lack of demonstrated efficacy. Use is contraindicated in a patient with an unprotected airway, in a patient in whom its use increases the risk and severity of aspiration, and in a patient who is at risk of hemorrhage or gastrointestinal perforation due to pathology (Benson, 2013; Vale, 2004).
- Single-dose activated charcoal: Use may be considered in a patient who presents within 1 hour of the ingestion (Chyka, 2005). Use is contraindicated in a patient who has a diminished level of consciousness unless the airway is protected.

Activated charcoal in water: Single dose: Oral or NG:

Infants <1 year: 10-25 g; **Note:** Although dosing by body weight is reported in children (0.5-1 g/kg) and published in many resources, there are no data or scientific rationale to support this recommendation (Chyka, 2005).

Infants and Children 1-12 years: 25-50 g

Children >12 years and Adults: 25-100 g

Calcium Channel Blockers – Comparative Pharmacokinetics Updated 7/31/13

Lexi-Tox

Calcium Channel Blockers Updated 10/2/13

Drug Allergy and Idiosyncratic Reactions

Calcium Channel Blocker, Dihydropyridine Allergy

臨床情境 #9 - 產生問題

- 李先生，65 歲，新診斷為肺腺癌，EGFR (-)，且有縱膈腔淋巴結轉移和肋骨轉移的情形，屬 Stage IV。
- 此次住院準備接受第一次的化學治療 (Alimta® + Carboplatin®)，藥師接到醫師開立的住院首次化療用藥指導單，準備對李先生進行用藥衛教。



臨床情境 #9 - 選擇檢索工具


Lexicomp®

Interactions Drug I.D. Calculators I.V. Compatibility **Patient Education** Toxicology

Lexicomp Online

Limit Search to ▾

Enter drug, disease, or other keyword **Search**

 Explore by General Category:

- Drugs
- Diseases
- Toxicology
- Patient Education
- Laboratory
- International Drugs

臨床情境 #9 - 輸入檢索字詞

Lexicomp®

Enter drug, disease, or other keyword **Search** Limit Search to

Feedback Corporate User Guide Logout

Select Language Recent Documents

Interactions Drug I.D. Calculators I.V. Compatibility Patient Education Toxicology

More Clinical Tools

Patient Education provided by Lexicomp and UpToDate

Packet Contents

Search

Conditions/Procedures

Conditions
Procedures
Discharge Instructions
Healthy Living
Chinese

Search
Alimta
Adult M

Medications

Adult Medications
Pediatric Medications
Chinese

Print Options

☐ English copy of non-English leaflets
☐ Patient Summary
☐ Signature Page

Font Size

Regular (12pt)

Clear **Store Current Packet**

- 提供多達 19 種語言之用藥指導單和疾病衛教單張
- English、Chinese (繁、簡)、Vietnamese、Korean、Japanese、Spanish 等...

臨床情境 #9 - 選擇單張內容並儲存

Lexicomp® [Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

Enter drug, disease, or other keyword Limit Search to

[Home](#) [Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#) [Select Language](#) [Recent Documents](#) [More Clinical Tools](#)

Patient Education provided by Lexicomp and UpToDate

Packet Contents

Conditions/Procedures

Conditions
Procedures
Discharge Instructions
Healthy Living
Chinese

Medications

Adult Medications

☒ Alimta

Pediatric Medications
Chinese

Print Options

☐ English copy of non-English leaflets
☒ Patient Summary
☐ Signature Page

Font Size

Regular (12pt)

Search

Search Patient Education

Alimta

Enter Packet Name

⚠ Do NOT use any patient specific information in the packet name.
This could be a violation of HIPAA requirements.

Enter Packet Name

臨床情境 #9 - 預覽內容並列印

Lexicomp® [Feedback](#) [Corporate](#) [User Guide](#) [Logout](#)

Enter drug, disease, or other keyword [Search](#) Limit Search to [Select Language](#) [Recent Documents](#)

[Interactions](#) [Drug I.D.](#) [Calculators](#) [I.V. Compatibility](#) [Patient Education](#) [Toxicology](#) [More Clinical Tools](#)

Patient Education provided by Lexicomp and UpToDate

Packet Contents [Search](#) [Browse](#) [Stored Packets](#) [Preview Current Packet](#)

Conditions/Procedures

Conditions
Procedures
Discharge Instructions
Healthy Living
Chinese

Medications

Adult Medications
X Alimta
Pediatric Medications
Chinese

Print Options

☐ English copy of non-English leaflets
☒ Patient Summary
☐ Signature Page

Font Size
Regular (12pt)

[Clear](#) [Store Current Packet](#)

Pemetrexed [Refresh](#) [Help](#) [Print](#)
Printed on Thu, May 23, 2013

Pronunciation (pem e TREKS ed)
美國廠牌 Alimta
加拿大廠牌 Alimta®

此藥有哪些副作用？

不要服用此藥，如果：

- 結您對
- 結您對
- 結你已
- 結您在

最佳的用藥方法為何？

- 此藥用於靜脈血管注射。
- 治療前 1 週、治療期間及治療後 3 週內請服用葉酸。
- 醫務人員將在治療開始前1週、治療期間每9週為您注射一次維他命B12。
- 治療期間，可預防皮疹的一種藥物服用3天。請諮詢醫務人員。

使用此藥時，請注意：

- 結您患有腎臟疾病，請告知您的醫師。
- 血液檢驗。請告知醫療人員。
- 告訴牙醫、外科醫師和其他醫師，您正在使用此藥。
- 與您的醫師一起核對您正使用的所有藥物。該藥與某些特定藥物混合效果不佳。
- 隨身攜帶一份您所有藥物的清單（處方藥、天然滋補品、維他命劑、非處方藥）。將清單交給您的醫師。
- 請在使用下列藥物或食材前諮詢醫護人員：aspirin（阿斯匹靈）、薄血藥、大蒜、人參、銀杏、ibuprofen（普羅芬/異丁苯乙酸）或類似藥品、止痛藥、或維他命 E。

舌頭或喉嚨腫脹；

Q&A

業務專員 陳永祥

tesochen@flysheet.com.tw

資料庫為**輔助**醫療人員決策之用
，應用時應**綜合**各文獻內容(包含
仿單.Lexicomp, Micromedex等)
及臨床判斷，以求周全。